Drug Development EXECUTIVE Pace Analytical? Life Sciences: Delivering Science Better; Advancing Novel Therapies through the Clinic to Commercialization

Frank Tagliaferri

首页> 外文期刊>Drug Delivery & Technology >Drug Development EXECUTIVE Pace Analytical? Life Sciences: Delivering Science Better; Advancing Novel Therapies through the Clinic to Commercialization

【24h】

Drug Development EXECUTIVE Pace Analytical? Life Sciences: Delivering Science Better; Advancing Novel Therapies through the Clinic to Commercialization

机译：药物开发行政步伐分析？生命科学：提供科学更新; 通过诊所向商业化推进新的疗法

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Our investment in state-of-the-art facilities and highly trained experts emphasizes our commitment to advancing therapies and delivering positive customer experiences across all phases of pharmaceutical and biopharmaceutical development. From early stage research and development, to clinical trials materials production and GMP manufacturing support, our 400+ scientists are dedicated to providing the best and most reliable pharmaceutical development services. Pace Analytical? Life Sciences (PLS) is well-equipped to handle almost any project regardless of scope or complexity. We recently interviewed Frank Tagliaferri, PhD, Vice President of Pharmaceutical Development at PLS to discuss his experiences with the company and its growth.

机译：我们对最先进的设施和高度训练的专家的投资强调了我们对推进疗法的承诺，并在药物和生物制药的所有阶段提供积极的客户体验。从早期的研发，临床试验材料的生产和GMP制造支持，我们的400多家科学家们致力于提供最佳，最可靠的药业开发服务。节奏分析？无论范围或复杂程度如何，生命科学（PLS）都可以处理几乎任何项目。我们最近采访了PLS制药开发副总裁博士，博士学位讨论了公司的经验及其增长。

著录项

来源
《Drug Delivery & Technology》 |2021年第2期|共3页
作者
Frank Tagliaferri;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Drug Development EXECUTIVE Quotient Sciences: Breaking Down the Silos Between Drug Substance & Drug Product [J] . Mark Egerton Drug Delivery & Technology . 2021,第5期

机译：药物开发行政用品科学：拆除药物物质与amp之间的筒仓; 药品
2. Retraction: Nuclear receptors as targets for drug development: Crosstalk between peroxisome proliferator-activated receptor γ and cytokines in bone marrow-derived mesenchymal stem cells (Journal of Pharmacological Sciences (2005) 97, (184-189)) [J] . TakadaI., SuzawaM., KatoS. Journal of pharmacological sciences. . 2013,第2期

机译：收缩：核受体作为药物开发的靶标：过氧化物酶体增殖物激活的受体γ与骨髓间充质干细胞中的细胞因子之间的串扰（药理学杂志（2005）97，（184-189））
3. EuroTIDES 2008--Informa Life Sciences' Ninth Annual Conference. Oligonucleotides, RNAi and peptides for the drug development and manufacturing industry. [J] . Morimoto B IDrugs: the investigational drugs journal . 2009,第2期

机译：EuroTIDES 2008 –信息生命科学第九届年会。用于药物开发和制造行业的寡核苷酸，RNAi和肽。
4. Applications of space science and space technology to life sciences: a model for future research commercialization efforts [C] . Jeffrey H. Matsuura AIAA Life Sciences and Space Medicine Conference '95 April 3-5, 1995/Houston, TX . 1995

机译：空间科学和空间技术在生命科学中的应用：未来研究商业化工作的模型
5. Development of nuclear analytical methods in support of the life sciences. [D] . Cheng, Ting-pang. 1994

机译：开发支持生命科学的核分析方法。
6. Safeguarding advances in the life sciences: The International Council for the Life Sciences is committed to becoming the authoritative source for identifying and managing biological risks [O] . Terence Taylor, (Author photo) 2006

机译：保障生命科学的进步：国际生命科学理事会致力于成为鉴定和管理生物风险的权威来源
7. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary A Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the North American Society of Pacing and Electrophysiology31This document was approved by the American College of Cardiology Board of Trustees in August 2001, the American Heart Association Science Advisory and Coordinating Committee in August 2001, and the European Society of Cardiology Board and Committee for Practice Guidelines and Policy Conferences in August 2001.32When citing this document, the American College of Cardiology, the American Heart Association, and the European Society of Cardiology would appreciate the following citation format: Fuster V, Rydén LE, Asinger RW, Cannom DS, Crijns HJ, Frye RL, Halperin JL, Kay GN, Klein WW, Lévy S, McNamara RL, Prystowsky EN, Wann LS, Wyse DG. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol 2001;38:1231–65).33This document is available on the World Wide Web sites of the American College of Cardiology (http://www.acc.org), the American Heart Association (http://www.americanheart.org), the European Society of Cardiology (http://www.escardio.org), and the North American Society of Pacing and Electrophysiology (http://www.naspe.org). Single reprints of this document (the Executive Summary and Summary of Recommendations) is available by calling 800-253-4636 (US only) or writing the American College of Cardiology, Educational Services, 9111 Old Georgetown Road, Bethesda, MD 20814-1699. To obtain a reprint of the complete guidelines published in the mid-October issue of the European Heart Journal, call +44 207 424 4200 or +44 207 424 4389, fax +44 207 424 4433, or write Harcourt Publishers Ltd, European Heart Journal, ESC Guidelines - Reprints, 32 Jamestown Road, London, NW1 7BY, United Kingdom. To purchase additional reprints, specify version and reprint number (Executive Summary 71-0208; Full-Text 71-0209): up to 999 copies, call 800-611-6083 (US only) or fax 413-665-2671; 1000 or more copies, call 214-706-1466, fax 214-691-6342; or E-mail pubauth@heart.org. [O] . Fuster Valentin, Rydén Lars E, Asinger Richard W, 2001

机译：ACC / AHA / ESC治疗房颤患者的指南：执行摘要美国心脏病学会/美国心脏协会实践指南工作组和欧洲心脏病学会实践指南委员会和政策会议的报告与北美起搏和电生理学会合作制定的《房颤患者治疗管理指南》 31该文件于2001年8月获得美国心脏病学会理事会的批准，于8月获得美国心脏协会科学咨询与协调委员会的批准2001年，以及2001年8月召开的欧洲心脏病学会理事会和实践指南与政策委员会会议。32引用该文件时，美国心脏病学会，美国心脏协会和欧洲心脏病学会将赞赏以下引用格式：Fuster V，RydénLE， Asinger RW，Cannom DS，Crijns HJ，Frye RL，Halperin JL，Kay GN，Klein WW，LévyS，McNamara RL，Prystowsky EN，Wann LS，Wyse DG。 ACC / AHA / ESC治疗房颤患者的指南：执行摘要：美国心脏病学会/美国心脏协会实践指南工作组和欧洲心脏病学会实践指南委员会和政策会议的报告（委员会制定房颤患者治疗指南）。 J Am Coll Cardiol 2001; 38：1231-65）.33本文档可在美国心脏病学会（http://www.acc.org），美国心脏协会（http://www.acc.org）的万维网站点上找到。 www.americanheart.org），欧洲心脏病学会（http://www.escardio.org）和北美起搏和电生理学会（http://www.naspe.org）。可致电800-253-4636（仅适用于美国）或写信给美国心脏病，教育服务学院，地址为9111 Old Georgetown Road，Bethesda，MD 20814-1699，获得本文档的单版（执行摘要和建议摘要）。要获得《欧洲心脏杂志》十月中发行的完整指南的重印本，请致电+44 207 424 4200或+44 207 424 4389，传真+44 207 424 4433，或写信给《欧洲心脏杂志》 Harcourt Publishers Ltd ，ESC指南-转载，英国伦敦詹姆斯敦路32号，NW1 7BY。要购买其他重印本，请指定版本和重印编号（执行摘要71-0208；全文71-0209）：最多999份，请致电800-611-6083（仅限美国）或传真413-665-2671；或1000或更多副本，请致电214-706-1466，传真214-691-6342;或发送电子邮件至pubauth@heart.org。
8. Recent Advances in Analytical Methodology in the Life Sciences. Proceedings of the Food and Drug Administration Science Symposium (8th) Held at Bethesda, Maryland on August 16-18, 1982 [R] . 1982

机译：生命科学分析方法学的最新进展。食品药品管理局科学研讨会论文集（第8期）于1982年8月16日至18日在马里兰州贝塞斯达举行

Drug Development EXECUTIVE Pace Analytical? Life Sciences: Delivering Science Better; Advancing Novel Therapies through the Clinic to Commercialization

摘要

著录项

相似文献

相关主题

期刊订阅